Author(s): Meghana S. Kamble*, Krunal K. Vaidya, Pravin P. Aute and Rohini P. Chavan
The aim of the present study was to develop patient-friendly tablets of antihypertensive amlodipine besylate to increase patient’s adherence to antihypertensive therapy. The patient might not strictly follow the dosage regimen and skip doses, reasons being trouble in swallowing tablets, unavailability of waterduring traveling to take the tablets. Mouth-dissolving tablets (MDT) provide excellent option to increase rate of persistence to therapeutic regimen. These tablets rapidly disintegrate in mouth in less than a minute, so no need to swallow whole tablet andno need of water to take it. In the present study bitterly tasting antihypertensive drug amlodipine besylate was successfully taste-masked by complexing with β –cyclodextrin (β-CD) and formulated as MDT. Six MDT formulations were prepared and evaluated for hardness, friability, in vitro disintegration time, wetting time, drug content and in vitro drug release. Formulation F5 was found to be optimum with 15.3 sec in vitro disintegration time, 2.83 kg/cm2 hardness, 0.44% friability and 98.09% drug release in 30 minutes.